Liliane Massade | Targeted therapy | Innovation in Neuroscience Award

Posted on by Neuroscientists

Liliane Massade | Targeted therapy | Innovation in Neuroscience Award

Dr. Liliane Massade, INSERM, France.

Dr. Liliane Massade is a visionary research leader whose work integrates molecular biology, nanotechnology, and translational medicine. From her academic roots in Lebanon to her pioneering research in France, she has achieved significant milestones, including the development of siRNA-based therapies for Charcot-Marie-Tooth disease and innovations in neurodegenerative and cancer treatments. Her career spans decades of groundbreaking discoveries, interdisciplinary collaborations, and impactful mentorship. With over 78 publications, patents, and numerous awards, Dr. Massade’s contributions are both scientifically profound and globally influential.

Profile

Orcid

🌟 Early Academic Pursuits

Dr. Liliane Massade’s academic journey began with her passion for biology and education. After earning her Master’s in Biology from Lebanese University in 1982, she followed her calling as a teacher, obtaining a Teaching Diploma from Ecole Normale, Lebanon, in 1981. Her thirst for knowledge led her to Paris Diderot University, where she completed an Advanced Studies Diploma (DEA) in Population Genetics and Evolution in 1986. By 1990, she had earned her Ph.D. in Population Genetics and Evolution, marking the start of her illustrious career. In 1996, she achieved the Authorization to Supervise Research (HDR), solidifying her role as a mentor and leader in her field.

🔬 Professional Endeavors

Dr. Massade’s career has been a symphony of innovation, leadership, and groundbreaking research. Since 2020, she has led a cutting-edge team at U1195 INSERM, Bicêtre University Hospital, focusing on targeted therapies for chemotherapy-induced peripheral neuropathies. Prior to this, she helmed teams at UMR 8203 CNRS, Gustave Roussy Institute, where she advanced anti-cancer therapies and explored molecular targets in thyroid cancer. Her earlier work at INSERM and CNRS saw her delve into estradiol signaling in breast cancer and enzymes in drug metabolism, laying the foundation for her expertise in molecular biology and translational medicine.

💡 Contributions and Research Focus

Dr. Massade’s pioneering spirit has transformed the fields of neurodegenerative diseases and oncology. She is celebrated for her groundbreaking siRNA-based therapies targeting PMP22, which have opened new horizons for Charcot-Marie-Tooth disease treatment. Her innovations extend beyond therapy, as her patented methods in nucleic acid transfer highlight her interdisciplinary approach. With a focus on integrating biology, chemistry, and nanotechnology, she leads research that merges fundamental science with clinical application, offering hope for conditions like peripheral neuropathy and neurodegeneration.

🏆 Accolades and Recognition

Throughout her career, Dr. Massade has earned prestigious accolades, including the Outstanding Achievement Award at the World Congress on Advances in Oncology in 2013 and the JW Griffin Prize for Regeneration from the Peripheral Nerve Society in 2021. Her impact is further underscored by her extensive publication record, with 78 works, an H-index of 26, and over 49 invited talks at international conferences. These honors reflect her global influence and her ability to inspire the next generation of researchers.

🌍 Impact and Influence

Dr. Massade’s contributions extend beyond her lab, as she evaluates research programs for renowned organizations like the ERC, ANR, and ARC. As a member of international committees such as LaBEX NanoSaclay, she ensures the advancement of cutting-edge nanotechnology. Her mentorship has shaped the careers of 10 postdoctoral researchers, 11 Ph.D. candidates, and 31 Master’s students, demonstrating her commitment to nurturing scientific talent.

🔗 Legacy and Future Contributions

As the co-founder of MAAsiRNA, Dr. Massade exemplifies the translation of research into real-world impact. With €7 million raised to develop therapies targeting PMP22, her work bridges the gap between science and patient care. Her vision for the future includes continued exploration of siRNA therapies and the development of innovative approaches to neuroprotection and cancer treatment. Her legacy is one of scientific excellence, interdisciplinary collaboration, and unwavering dedication to improving lives through research.

📚Publications

  • GRT-X Stimulates Dorsal Root Ganglia Axonal Growth in Culture via TSPO and Kv7.2/3 Potassium Channel Activation
    Authors: Léa El Chemali, Suzan Boutary, Song Liu, Guo-Jun Liu, Ryan J. Middleton, Richard B. Banati, Gregor Bahrenberg, Rainer Rupprecht, Michael Schumacher, Liliane Massaad-Massade
    Year: 2024

 

  • Optimizing Structure and Activity of the Squalenoyl-siRNA Nanoparticles
    Author: Liliane Massaad-Massade
    Year: 2023

 

  • Mutation of Proteolipid Protein 1 Gene: From Severe Hypomyelinating Leukodystrophy to Inherited Spastic Paraplegia
    Authors: Guy Khalaf, Claudia Mattern, Mélina Begou, Odile Boespflug-Tanguy, Charbel Massaad, Liliane Massaad-Massade
    Year: 2022

 

  • The Mitochondrial Translocator Protein (TSPO): A Key Multifunctional Molecule in the Nervous System
    Authors: Léa El Chemali, Yvette Akwa, Liliane Massaad-Massade
    Year: 2022

 

  • Supramolecular Organization and Biological Interaction of Squalenoyl siRNA Nanoparticles
    Authors: Marie Caillaud, Frédéric Gobeaux, Miryana Hémadi, Suzan Boutary, Patrick Guenoun, Didier Desmaële, Patrick Couvreur, Frank Wien, Fabienne Testard, Liliane Massaad-Massade
    Year: 2021

 

  • Squalenoyl siRNA PMP22 Nanoparticles Are Effective in Treating Mouse Models of Charcot-Marie-Tooth Disease Type 1A
    Author: Liliane Massaad-Massade
    Year: 2021

 

  • Treating PMP22 Gene Duplication-Related Charcot-Marie-Tooth Disease: The Past, the Present, and the Future
    Author: Liliane Massaad-Massade
    Year: 2020

 

  • Small Interfering RNA From the Lab Discovery to Patients’ Recovery
    Authors: Marie Caillaud, Mévidette El Madani, Liliane Massaad-Massade
    Year: 2020

 

  • Newly Identified LMO3-BORCS5 Fusion Oncogene in Ewing Sarcoma at Relapse Is a Driver of Tumor Progression
    Author: Liliane Massaad-Massade
    Year: 2019

 

  • A Novel Therapeutic Approach to Colorectal Cancer in Diabetes: Role of Metformin and Rapamycin
    Author: Liliane Massaad-Massade
    Year: 2019

 

  • Discovery of New Fusion Transcripts in a Cohort of Pediatric Solid Cancers at Relapse and Relevance for Personalized Medicine
    Author: Liliane Massaad-Massade
    Year: 2019

 

🌟 Conclusion

Dr. Liliane Massade is a beacon of innovation and leadership in molecular biology and targeted therapies. From her academic beginnings in Lebanon to her groundbreaking contributions in France, she has forged a path of excellence that inspires scientists worldwide. With her unparalleled expertise and passion, she continues to redefine the possibilities of modern medicine, leaving an indelible mark on science and humanity.

Hui-Hsin Ko | Oral oncology | Best Researcher Award

Posted on by Neuroscientists

Dr. Hui-Hsin Ko | Oral oncology | Best Researcher Award

Dr . Hui-Hsin Ko National Taiwan University Hsin-Chu Hospital Taiwan

Dr. Hui-Hsin Ko is an Assistant Professor and the Head of the Oral & Maxillofacial Surgery Division at National Taiwan University Hsin-Chu Hospital. With a DDS, MS, and PhD from National Taiwan University, she has extensive expertise in oral and maxillofacial surgery, specializing in cancer surgeries, temporomandibular joint (TMJ) surgeries, and zygomatic implantation. Dr. Ko’s research focuses on oral squamous cell carcinoma, with multiple publications in SCI-indexed journals. She has contributed significantly to the field of cancer research by exploring biomarkers such as AKR1B10, advancing both the understanding and treatment of oral cancers. Dr. Ko’s achievements in research and clinical practice have set a high standard for innovation in her field.

 

profile

scopus

Academic and Professional Background 🎓

Dr. Hui-Hsin Ko is a Clinical Assistant Professor at National Taiwan University and the Head of the Oral & Maxillofacial Surgery Division at National Taiwan University Hospital, Hsin-Chu Branch. She holds a DDS, MS, and PhD from National Taiwan University, with specialization in oral and maxillofacial surgery. Her expertise includes temporomandibular joint surgery, cancer surgery, and zygomatic implantation. A diplomate of the Taiwan Board of Oral and Maxillofacial Surgery, Dr. Ko has authored several publications, significantly contributing to oral squamous cell carcinoma research.

Research and Innovations 💡

Completed/Ongoing Research Projects: AKR1B10-related, TMJ arthroscopy-related, oral cancer-related.Citation Index: Information available on indexed platformsConsultancy/Industry Projects: To be updated Books Published (ISBN): No books published yet.Patents Published/Under Process: To be updated.Journals Published (SCI, Scopus, etc.): Multiple articles published in SCI-indexed journals

Editorial Appointments ✍️

To be updated.

Collaborations 🤝

Dr. Ko has actively collaborated with medical professionals and researchers in Taiwan to advance studies in oral squamous cell carcinoma and oral health-related surgeries.

Professional Memberships 📜

Diplomate of the Taiwan Board of Oral and Maxillofacial Surgery.Member of various oral and maxillofacial surgical associations

Areas of Research 🔬

Oral squamous cell carcinoma.Temporomandibular joint surgery.Zygomatic implantation.Cancer surgery

Contributions 🌟

Dr. Hui-Hsin Ko has significantly contributed to cancer research, especially in identifying biomarkers for oral squamous cell carcinoma progression. Her work on AKR1B10 levels has opened new pathways in understanding the poor prognosis of the disease. She has also explored advanced surgical techniques, including TMJ surgery and zygomatic implantation, contributing to improved patient outcomes.

 

📚 Publications

  • Title: The dental implant survival rate in 18 patients with post-operation revolutionary jaw reconstruction using free fibular flap, dental implants, and overdentures
    Author(s): Ko, H.-H., Chou, C.-H., Cheng, S.-J.
    Year: 2024

 

  • Title: Fibroblast growth factor 5 expression predicts the progression of oral squamous cell carcinoma
    Author(s): Shie, W.-Y., Cheng, S.-J., Chen, K.-C., Hou, H.-H., Elizabeth Chou, H.-Y.
    Year: 2024

 

  • Title: Oleanolic acid inhibits aldo-keto reductase family 1 member B10-induced cancer stemness and avoids cisplatin-based chemotherapy resistance via the Snail signaling pathway in oral squamous cell carcinoma cell lines
    Author(s): Ko, H.-H., Chou, H.-Y.E., Hou, H.-H., Yen-Ping Kuo, M., Cheng, S.-J.
    Year: 2024

 

  • Title: Prosthetic-Driven Autotransplantation with the Assistance of Medical Image-Processing Software and a Real-Time Navigation System: A Case Report
    Author(s): Chang, H.-M., Ko, H.-H., Chi, C.-W., Lin, I.-P., Chen, S.-H.
    Year: 2024

 

  • Title: Evaluation of the prognostic and therapeutic potential of inhibin beta B for oral squamous cell carcinoma
    Author(s): Chung, Y.-Y., Cheng, S.-J., Ko, H.-H., Shie, W.-Y., Elizabeth Chou, H.-Y.
    Year: 2024

 

  • Title: Metastasis and immunosuppression promoted by mtDNA and PD-L1 in extracellular vesicles are reversed by WGP β-glucan in oral squamous cell carcinoma
    Author(s): Ko, H.-H., Peng, H.-H., Cheng, A.N., Lee, A.Y.-L., Cheng, S.-J.
    Year: 2023

 

  • Title: Lysyl oxidase-like 2 promotes stemness and enhances antitumor effects of gefitinib in head and neck cancer via IFIT1 and IFIT3
    Author(s): Lu, Y.-J., Deng, Y.-T., Ko, H.-H., Kuo, M.Y.-P., Cheng, S.-J.
    Year: 2023

 

  • Title: ZNF582 hypermethylation as a prognostic biomarker for malignant transformation of oral lesions
    Author(s): Juan, Y.-C., Su, Y.-F., Bai, C.-H., Fwu, C.-W., Cheng, S.-J.
    Year: 2023

 

  • Title: β-glucan therapy converts the inhibition of myeloid-derived suppressor cells in oral cancer patients
    Author(s): Lo, Y.-W., Lee, A.Y.-L., Liu, Y.-C., Chiang, C.-P., Cheng, S.-J.
    Year: 2022

 

  • Title: Upregulated NPM1 is an independent biomarker to predict progression and prognosis of oral squamous cell carcinomas in Taiwan
    Author(s): Peng, H.-H., Ko, H.-H., Chi, N.-C., Kuo, M.Y.-P., Cheng, S.-J.
    Year: 2020

 

Conclusion

Dr. Hui-Hsin Ko’s extensive background in oral and maxillofacial surgery, coupled with her impressive research contributions to the understanding of oral squamous cell carcinoma, makes her a strong candidate for the Best Researcher Award. Her dedication to advancing cancer research, her innovative surgical techniques, and her collaborative efforts in the medical field demonstrate her leadership and impact. Dr. Ko has not only excelled in her clinical practice but has also significantly contributed to scientific advancements that benefit patients globally.